• linkedin
  • Increase Font
  • Sharebar

    CPE UPDATE. Insulin therapy for diabetes care management


    CPE UPDATE JULY 1, 2015

    Insulin therapy for diabetes care management

    Session Code: 15DT20-VYJ93

    ACPE #0009-9999-15-20-H01-P 

    Grant Funding: Merck Sharp & Dohme Corp.

    Initial release date: 7/1/2015

    Expiration date: 7/1/2018

    Editor’s Note: This CPE activity, which was first published in December 2012 for Drug Topics (print edition and online), has been updated and reaccredited as of July 1, 2015.

    Author: Devra K. Dang, PharmD, BCPS, CDE, FNAP.

    Devra K. Dang, PharmD, BCPS, CDE, FNAP, is associate clinical professor, University of Connecticut School of Pharmacy, Storrs, Conn. Dr. Dang updated the article.

    Goal: To discuss the place in therapy, efficacy, adverse events, administration, and patient education for insulin therapy for the management of diabetes

    To read and print the article with TEST QUESTIONS, click here

    To proceed to the online exam and earn up to 2 CPE credits, 
    click here to log in with the session code 15DT20-VYJ93.

    Copy the session code — 15DT20-VYJ93— before logging into the Online CE Center
    When the page for the Online CE Center opens, paste the session code into the appropriate field, under your NABP ID.


    The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php.

    To review your registration page to ensure the data is up to date, or to register,
    go to https://web2.uconn.edu/pharmacyce/program_register.php.

    For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/.

    Jiehyun Lee, PharmD
    Jiehyun Lee, PharmD, is medication management clinic supervisor at Backus Hospital, Norwich, Conn., and adjunct assistant clinical ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available